MX377995B - Moléculas de unión al receptor bag3 para uso como un medicamento. - Google Patents

Moléculas de unión al receptor bag3 para uso como un medicamento.

Info

Publication number
MX377995B
MX377995B MX2016001691A MX2016001691A MX377995B MX 377995 B MX377995 B MX 377995B MX 2016001691 A MX2016001691 A MX 2016001691A MX 2016001691 A MX2016001691 A MX 2016001691A MX 377995 B MX377995 B MX 377995B
Authority
MX
Mexico
Prior art keywords
receptor binding
binding molecules
medicine
bag3 receptor
bag3
Prior art date
Application number
MX2016001691A
Other languages
English (en)
Other versions
MX2016001691A (es
Inventor
Maria Caterina Turco
Original Assignee
Fibrosys S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrosys S R L filed Critical Fibrosys S R L
Publication of MX2016001691A publication Critical patent/MX2016001691A/es
Publication of MX377995B publication Critical patent/MX377995B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere al uso de moléculas de unión al receptor BAG3 como un medicamento, particularmente para el uso en el tratamiento de enfermedades de naturaleza inmune, inflamatoria, cardiovascular, neoplásica y/o degenerativa.
MX2016001691A 2013-08-07 2014-07-23 Moléculas de unión al receptor bag3 para uso como un medicamento. MX377995B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001351A ITMI20131351A1 (it) 2013-08-07 2013-08-07 Molecole leganti il recettore di bag3 per uso terapeutico.
PCT/IB2014/063352 WO2015019230A1 (en) 2013-08-07 2014-07-23 Bag3 receptor binding molecules for use as a medicament

Publications (2)

Publication Number Publication Date
MX2016001691A MX2016001691A (es) 2016-11-30
MX377995B true MX377995B (es) 2025-03-10

Family

ID=49354779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001691A MX377995B (es) 2013-08-07 2014-07-23 Moléculas de unión al receptor bag3 para uso como un medicamento.

Country Status (13)

Country Link
US (1) US9963514B2 (es)
EP (1) EP3030320B1 (es)
JP (1) JP6511445B2 (es)
KR (1) KR20160037951A (es)
AU (1) AU2014304208B2 (es)
BR (1) BR112016002619A2 (es)
CA (1) CA2920586C (es)
ES (1) ES2731257T3 (es)
IL (1) IL243857A0 (es)
IT (1) ITMI20131351A1 (es)
MX (1) MX377995B (es)
RU (1) RU2016107874A (es)
WO (1) WO2015019230A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019017297A (ja) * 2017-07-17 2019-02-07 杭州優瑪達生物科技有限公司Ｈａｎｇｚｈｏｕ ＵＭｏｔｏｒ Ｂｉｏｔｅｃｈ Ｃｏ．， ＬＴＤ． 天然由来および／または自己集合技術によって得られる生体膜、生体膜性質を有する閉合構造または細胞内区画およびその作製方法と応用
WO2019020734A1 (en) * 2017-07-28 2019-01-31 Biouniversa S.R.L. ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
WO2019237002A1 (en) 2018-06-08 2019-12-12 Temple University - Of The Commonwealth System Of Higher Education Optimizing bag3 gene therapy
SG11202108140SA (en) 2019-02-12 2021-08-30 Medpacto Inc Anti-bag2 antibody and methods of treating cancer
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
ITMI20130403A1 (it) 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico

Also Published As

Publication number Publication date
EP3030320A1 (en) 2016-06-15
ES2731257T3 (es) 2019-11-14
AU2014304208B2 (en) 2020-02-20
JP2016527301A (ja) 2016-09-08
JP6511445B2 (ja) 2019-05-15
AU2014304208A1 (en) 2016-02-25
WO2015019230A1 (en) 2015-02-12
US20160168255A1 (en) 2016-06-16
CA2920586C (en) 2023-09-12
BR112016002619A2 (pt) 2017-08-01
IL243857A0 (en) 2016-04-21
MX2016001691A (es) 2016-11-30
ITMI20131351A1 (it) 2015-02-08
EP3030320B1 (en) 2019-03-20
RU2016107874A (ru) 2017-09-14
KR20160037951A (ko) 2016-04-06
US9963514B2 (en) 2018-05-08
CA2920586A1 (en) 2015-02-12
RU2016107874A3 (es) 2018-06-15

Similar Documents

Publication Publication Date Title
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY35399A (es) Conjugados de fármacos con anticuerpos
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
CR20150358A (es) Derivados de exendina-4 fucionalizada
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX376058B (es) Uso de peptidos glp-1 de accion prolongada.
AR095232A1 (es) Métodos y composiciones para el control de malezas
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
PH12017501979A1 (en) Pharmaceutical compound